Redeye sees a soft Q2 report from Stille, marked by headwinds in the surgical instruments business, including supply chain issues and the ph...
Redeye’s initial view of the newly announced acquisition is positive.
Redeye updates its outlook on Stille following a report that missed expectations due to temporary supply constraints, portfolio rationalisat...
Redeye sees a softer-than-anticipated Q1 report from Stille, with sales and EBIT falling below our forecasts.
Redeye makes positive revisions to its financial projections and fair value range following Stille's year-end report.
Redeye’s initial take on Stille’s year-end report is positive.
Redeye leaves a short comment on Stille following the company's announcement that the CEO will resign in the June 2025.
Redeye makes negligible changes to its forecasts and valuation following Stille's Q3 report.
Redeye see a Q3 report from Stille confirming continued organic growth and expanding margins, albeit slightly softer than we had estimated.
Redeye returns with an updated take following a solid Q2 report from Stille, showing very minor deviations compared to our estimates.
Redeye see a Q2 report from Stille aligning with our estimates in terms of both sales and profitability.
Redeye upgrades its base case and forecasts following a solid Q1 report from Stille.
Redeye provides its comments on Stille following a solid Q1 report, which exceeded our sales estimates.
Redeye slightly raises estimates and fair value range following a strong Q4 from Stille where sales and EBIT exceeded our estimates.
Redeye regard Stille's Q4 report as strong as it came in slightly above our estimates in terms of both sales and EBIT.
Redeye adjusts its estimates and valuation following the SEK425m directed share issue and the acquisition of Fehling Instruments, which we b...
Redeye observes strong press releases from Stille announcing a SEK425m directed share issue to finance the acquisition of Fehling Instrument...
Redeye recognizes a solid Q3 report from Stille, which unveiled nuggets such as 18% y/y sales growth and EBIT margin of 16%, both slightly s...
Redeye see's an uplifting Q3 2023 report from Stille, which came in above our estimates both in terms of sales and EBIT, we note a particula...
Redeye returns with an update on Stille following its Q2 2023 report.
Redeye sees a Q2 2023 report from Stille that exceeds our estimates in terms of both sales and EBIT.
Redeye returns with an update on Stille following its Q1 2023 report.
Redeye considers Stille's Q1 2023 report relatively strong as it adjusted for the one-off item came in above our estimate both in terms of s...
Redeye leaves its comments on Stille’s Q4 2022 report.
Redeye returns with an updated view of Stille following the Q3 2022 report.
Redeye leaves its initial take on Stille's report for the third quarter of 2022, containing both positive and negative elements.
Redeye sees yet another strong quarterly report from Stille where the operating tables segment once again surprised us positively.
Redeye sees a strong Q1’22 report from Stille, where sales in the operating tables segment surprised us positively.
Redeye retains its positive long-term view of Stille following its year-end report, which came in largely in line with our expectations on a...
Redeye shares its initial take on Stille’s Q4’21 report, which came in slightly below our expectations on all levels except EBIT, which was ...
Redeye remains optimistic about the prospects of Stille following its Q2 report.
